tiprankstipranks
Advertisement
Advertisement
Alterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
PremiumThe FlyAlterity Therapeutics receives FDA feedback after second ATH434 Type C meeting
1M ago
Alterity Therapeutics presents new data analyses from ATH434 trial
Premium
The Fly
Alterity Therapeutics presents new data analyses from ATH434 trial
1M ago
Alterity Therapeutics appoints Cunningham to Board of Directors
Premium
The Fly
Alterity Therapeutics appoints Cunningham to Board of Directors
2M ago
Alterity Therapeutics provides corporate update
PremiumThe FlyAlterity Therapeutics provides corporate update
4M ago
Alterity Therapeutics highlights key 2026 objectives
Premium
The Fly
Alterity Therapeutics highlights key 2026 objectives
4M ago
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
Premium
The Fly
Alterity Therapeutics initiated with a Speculative Buy at Canaccord
6M ago
Meet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
PremiumThe FlyMeet Alterity Therapeutics: Fly exclusive interview with CEO David Stamler
7M ago
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
Premium
The Fly
Alterity Therapeutics presents analyses related to OH from ATH434-201 trial
7M ago
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
Premium
The Fly
Alterity Therapeutics reports cash balance of A$54.46M as of September 30
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100